GSK Plc (GSK)
52.46
+1.28
(+2.51%)
USD |
NYSE |
Jun 11, 10:25
GSK SG&A Expense (Quarterly) : 2.855B for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.855B |
| December 31, 2025 | 3.510B |
| September 30, 2025 | 3.020B |
| June 30, 2025 | 2.858B |
| March 31, 2025 | 2.607B |
| December 31, 2024 | 3.413B |
| September 30, 2024 | 4.940B |
| June 30, 2024 | 3.110B |
| March 31, 2024 | 2.646B |
| December 31, 2023 | 3.322B |
| September 30, 2023 | 2.906B |
| June 30, 2023 | 2.839B |
| March 31, 2023 | 2.604B |
| December 31, 2022 | 2.860B |
| September 30, 2022 | 2.417B |
| June 30, 2022 | 2.591B |
| March 31, 2022 | 3.814B |
| December 31, 2021 | 2.956B |
| September 30, 2021 | 2.313B |
| June 30, 2021 | 2.362B |
| March 31, 2021 | 3.347B |
| December 31, 2020 | 4.175B |
| September 30, 2020 | 3.447B |
| June 30, 2020 | 3.363B |
| March 31, 2020 | 3.726B |
| Date | Value |
|---|---|
| December 31, 2019 | 4.430B |
| September 30, 2019 | 3.565B |
| June 30, 2019 | 3.329B |
| March 31, 2019 | 3.226B |
| December 31, 2018 | 3.370B |
| September 30, 2018 | 3.293B |
| June 30, 2018 | 3.340B |
| March 31, 2018 | 3.216B |
| December 31, 2017 | 3.360B |
| September 30, 2017 | 3.019B |
| June 30, 2017 | 3.046B |
| March 31, 2017 | 3.038B |
| December 31, 2016 | 3.349B |
| September 30, 2016 | 3.007B |
| June 30, 2016 | 3.085B |
| March 31, 2016 | 3.101B |
| December 31, 2015 | 3.788B |
| September 30, 2015 | 3.026B |
| June 30, 2015 | 3.926B |
| March 31, 2015 | 3.361B |
| December 31, 2014 | 3.494B |
| September 30, 2014 | 3.335B |
| June 30, 2014 | 3.477B |
| March 31, 2014 | 3.276B |
| December 31, 2013 | 2.555B |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 140.76M |
| Johnson & Johnson | 6.034B |
| Eli Lilly & Co. | 2.934B |
| Merck & Co., Inc. | 2.70B |
| Novo Nordisk A/S | 2.070B |